A5063488239- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Retinoids in leukemia and cellular processes
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
- Hematological disorders and diagnostics
- Glycosylation and Glycoproteins Research
- Blood disorders and treatments
- Multiple Myeloma Research and Treatments
- Drug Transport and Resistance Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Cancer Treatment and Pharmacology
- Eosinophilic Disorders and Syndromes
- Drug-Induced Ocular Toxicity
- Cancer therapeutics and mechanisms
- T-cell and Retrovirus Studies
- Estrogen and related hormone effects
- Immune Cell Function and Interaction
- Fuel Cells and Related Materials
- Cancer Genomics and Diagnostics
- Platelet Disorders and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Lymphoma Diagnosis and Treatment
Hirosaki University
2004-2024
The University of Tokyo
1994-2023
Mitsubishi Tanabe Pharma Corporation
2023
University of Yamanashi
2023
Tokyo University of Marine Science and Technology
2012
Aichi Cancer Center
2001-2010
Yokohama City University Medical Center
2007
Aichi Shukutoku University
2007
Yokohama City University
2007
Bristol-Myers Squibb (Japan)
2007
An early phase II study of a new camptothecin analog and an inhibitor topoisomerase I, CPT-11, was conducted in 62 patients with refractory leukemia lymphoma by four different treatment schedules multiinstitutional cooperative study. CPT-11 therapy resulted complete remissions (CRs) three partial (PRs) 29 assessable non-Hodgkin's (NHL) patients, one PR Hodgkin's disease (HD), CR 11 acute lymphoblastic (ALL), 15 myelogenous (AML) patients. Single infusion 200 mg/m2 every 3 to 4 weeks produced...
PURPOSE We conducted a multicenter study of differentiation therapy with all-trans retinoic acid (ATRA) followed by intensive chemotherapy in patients newly diagnosed acute promyelocytic leukemia (APL) and analyzed the prognostic factors for predicting complete remission (CR), event-free survival (EFS), disease-free (DFS). PATIENTS AND METHODS All received ATRA until CR. If had an initial leukocyte count greater than 3.0 x 10(9)/L, they daunorubicin (DNR) behenoyl cytarabine (BHAC). During...
PURPOSE We analyzed complete remission (CR), disease-free survival (DFS), and event-free (EFS) rates in two groups of patients treated with either N4-behenoyl-1-beta-D-arabinosylcytosine (BHAC) or cytarabine, DFS without ubenimex, a biologic response modifier. PATIENTS AND METHODS Newly diagnosed acute myeloid leukemia (AML) were randomized to receive BHAC cytarabine as remission-induction combination chemotherapy courses consolidation therapy. After maintenance/intensification therapy, CR...
To identify factors associated with relapse-free survival (RFS), 80 patients newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, enrolled in a phase II study of imatinib-combined chemotherapy, were analyzed. The median follow-up surviving was 26.7 months (maximum, 52.5 months). Twenty-eight out 77 who had achieved CR relapsed. probability RFS 50.5% at 2 years. Multivariate analysis revealed that the presence secondary chromosome aberrations addition to t(9;22)...